Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
12/15/2010
Trade Name:
Uroxatral
Generic or Proper Name (*):
alfuzosin
Indications Studied:
Elevated detrusor leak point pressure of neurologic origin
Therapeutic Category:
Urology
Ages Studied:
2-16 years
Study #:
2
Study Type:
Efficacy/Safety
Study Design:
Single-Blind/Placebo/Parallel Group
No Patients:
172
No Centers:
49
No Countries:
15
BPCA(B), PREA(P):
B
Asian:
26
Black:
5
Other:
4
White:
137
Native Hawaiian or Pacific Islander:
0
American Indian/Alaska Native:
0
Hispanic/Latino:
0
Non-Hispanic/Non Latino:
0
Countries:
Canada (1), Estonia (1), France (3), Germany (2), India (4), Malaysia (1), Poland (6), Portugal (3), Russia (5), Serbia & Montenegro (3), Slovakia (2), Spain (5), Taiwan (2), Turkey (4), US (7)
-
-